DelNova has announced a partnership with Pace® Life Sciences to serve as its contract development and manufacturing organization (CDMO). This collaboration will enable DelNova to advance the clinical development of its lead candidate

BostonGene, a prominent provider of AI-based molecular and immune profiling solutions, has announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. This partnership enables BostonGene and JHUSOM to further explore and validate innovative precision medicine approaches.

Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company headquartered in Chicago, has expanded its portfolio of generic injectable products through an asset purchase agreement made by its parent company, Hong Kong King-Friend Industry Co., (HKF). This agreement has increased Meitheal's total portfolio of generic injectables to include 82 products.

A new state-of-the-art drug manufacturing facility has been launched in China, featuring cutting-edge automation technology.

India has announced new regulatory measures targeted at improving biopharmaceutical development and compliance.

Natera, a global leader in cell-free DNA testing, has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera. Signatera is Natera's personalized and tumor-informed molecular residual disease (MRD) test,

Advent International and Warburg Pincus have successfully completed their acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business.

Promontory Therapeutics Inc., a clinical-stage biotechnology company specializing in immunogenic small molecule approaches in oncology, has achieved the distinction of being the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC).

A leading biopharmaceutical company in Asia has introduced cutting-edge cold chain technology to enhance vaccine distribution efficiency.

ASEAN health authorities have released new regulations that will significantly impact biologics manufacturing processes across member countries.